Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
234 hedge funds and large institutions have $4.39B invested in Blueprint Medicines in 2020 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 88 increasing their positions, 67 reducing their positions, and 26 closing their positions.
85% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 26
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
36% more capital invested
Capital invested by funds: $3.24B → $4.39B (+$1.15B)
31% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 67
10% more funds holding
Funds holding: 213 → 234 (+21)
1.46% more ownership
Funds ownership: 102.35% → 103.81% (+1.5%)
21% less call options, than puts
Call options by funds: $43.6M | Put options by funds: $55.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$51.9M |
| 2 |
Holocene Advisors
New York
|
+$35.6M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$21.3M |
| 4 |
First Manhattan
New York
|
+$21M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$20.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$91.1M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$51.7M |
| 3 |
HM
HealthCor Management
New York
|
-$36.3M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$27.9M |
| 5 |
Alkeon Capital Management
New York
|
-$27.1M |
BPMC Hedge Fund Activity: Q2 2020 in Review
234 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2020, worth a combined $4.39B — up 36% from $3.24B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new BPMC positions and 26 closed out — a net gain of 22 holders — while 88 added to existing stakes and 67 trimmed.
The largest buyer was Candriam SCA, adding an estimated $51.9M. The largest seller was Fidelity Investments, cutting an estimated $91.1M.
- 234 institutional investors held Blueprint Medicines (BPMC) as of Q2 2020, up from 213 in Q1 2020.
- Funds reported $4.39B of Blueprint Medicines stock for Q2 2020, up 36% quarter-over-quarter.
- 48 funds opened new Blueprint Medicines positions in Q2 2020 and 26 closed out, a net change of +22 holders.
- The largest Blueprint Medicines buyer in Q2 2020 was Candriam SCA, an estimated $51.9M added.
- The largest Blueprint Medicines seller in Q2 2020 was Fidelity Investments, an estimated $91.1M sold.
Based on aggregated 13F filings for Q2 2020.